Argus Raises Price Target on Johnson & Johnson; Reaffirms “Buy” Rating (JNJ)

Argus reported on Thursday that it has increased its price target on healthcare product company, Johnson & Johnson (JNJ).

The firm has maintained a “Buy” rating on JNJ, and has increased its price target from $80 to $96. This price target suggests a 13% upside from the stock’s current price of $83.53.

Johnson & Johnson shares were mostly flat during Thursday morning trading. The stock has increased 32% in the past year.

The Bottom Line
Shares of Johnson & Johnson (JNJ) have a 2.91% yield, based on Thursday morning’s price of $83.71.

Johnson & Johnson (JNJ) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here